ClinicalTrials.gg
Drug

Pomalidomide clinical trials

Also written Pomalyst, CC-4047 and Imnovid.

studies test it
160
open now
27
in phase 3
18
first study started
2003

How each study uses pomalidomide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the pomalidomide studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
8 Feb 2013 · POMALYST · NDA 204026 (FDA, Drugs@FDA)
European Union
5 Aug 2013 · Imnovid (previously Pomalidomide Celgene) · EMEA/H/C/002682 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Pomalidomide
132
4-Aminothalidomide
20
Pomalidomide 4 MG Oral Capsule
3
Pom
3
Oral Pomalidomide
2

Brand

Pomalyst
62
Imnovid
28
Actimid
23

Development codes

CC-4047
57

In one entry with another drug

Given together, or one or the other

Pomalidomide and Dexamethasone
3

Studies by the year they started

160 studies that test it; most in 2022 (19)

Studies that test pomalidomide, by start year
YearStudies
20031
20075
20084
20094
20106
20117
201213
201310
201414
20155
20164
20177
20186
20198
20207
202116
202219
20235
20247
20255
20267

Who runs them

Industry 51 · Other 109

Celgene (22) · National Cancer Institute (NCI) (10) · Mayo Clinic (10) · Janssen Research & Development, LLC (5) · Weill Medical College of Cornell University (5) · Oncotherapeutics (4) · M.D. Anderson Cancer Center (4) · Fondazione EMN Italy Onlus (3)

Often tested with

Tested in the same studies.

Dexamethasone (68) · Daratumumab (17) · Carfilzomib (15) · Bortezomib (8) · Ixazomib (8) · Elotuzumab (7) · Belantamab mafodotin (7) · Cyclophosphamide (7)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 13 phase 3 studies under way

Pomalidomide is the comparator. A study of two new drugs counts under both.

Reaching primary completion within a year · 16, 2 in phase 3

Studies that test pomalidomide, phase 3 first.

Studies

Open first, then newest update. How each study uses pomalidomide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 160

See all 160 studies that test pomalidomide →

Given beside what is tested · 90 — pomalidomide is usual care or a partner of the new treatment

Showing 20 of 90.

As the comparator · 22 — what is tested is compared with pomalidomide

Showing 20 of 22.

Codes

What other systems call pomalidomide · ClinicalTrials.gg INT004483

  • MeSH (NLM) C467566pomalidomideConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) D2UX06XLB5POMALIDOMIDEConfirmed FDA, NLM, Wikidata
  • RxNorm 1369713Confirmed FDA, Wikidata
  • Wikidata Q7227206pomalidomideConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C72560PomalidomideOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.